Pancreatic Cancer Research

ResearcherUnited Arab Emirates UniversityNo recent work listed

Thomas Edward Adrian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5051-1111; OpenAlex author ID A5014474065. Sources: OpenAlex.

Their work

Papers
4 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
4
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper

Papers 4

  1. 1,2,3-Triazolyl ester of ketorolac (15K), a potent PAK1 blocker, inhibits both growth and metastasis of orthotopic human pancreatic cancer xenografts in mice. Last author DOI 10.5582/ddt.2019.01068↗
  2. Pharmacokinetics in Mouse and Comparative Effects of Frondosides in Pancreatic Cancer. Last author DOI 10.3390/md14060115↗
  3. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer. Last author DOI 10.1016/j.ejca.2014.01.002↗
  4. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma. First author DOI 10.1517/13543784.2014.933206↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. J. Al Shemaili · 2 shared papers, 2014–2016 · strength 0.10
  2. Rene Hennig · 1 shared paper, 2019 · strength 0.09
  3. Amal H. I. Al Haddad · 1 shared paper, 2014 · strength 0.09
  4. Robert Alan Newman · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.